Abstract
A phase II trial was conducted to evaluate the efficacy and toxicity of the Egorin's carboplatin dosing formula with 14-day oral etoposide in 38 elderly patients with small-cell lung cancer (SCLC). The overall response rate was 81%. Median survival times were 15.1 months for 16 limited-disease (LD) and 8.6 months for 22 extensive-disease (ED) patients. Myelosuppression was the principal side-effect. This regimen is an active regimen in the treatment of elderly SCLC patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Matsui, K., Masuda, N., Fukuoka, M. et al. Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer. Br J Cancer 77, 1961–1965 (1998). https://doi.org/10.1038/bjc.1998.325
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.325
This article is cited by
-
Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702
British Journal of Cancer (2007)
-
Bronchialkarzinom
Der Onkologe (2007)
-
Therapie des metastasierten kleinzelligen Lungenkarzinoms
Der Pneumologe (2007)
-
A phase I trial of carboplatin and etoposide for elderly (≥75 year-old) patients with small-cell lung cancer
Cancer Chemotherapy and Pharmacology (2006)
-
A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer
Cancer Chemotherapy and Pharmacology (2006)
